Protease Inhibitors in Neurologic Diseases
Proteases and their inhibitors are known or suspected to be implicated in many aspects of normal physiology and disease processes. Although the etiologies of all neurological diseases are not yet known, many are fatal and can be classified as hereditary. Among them are amyotrophic lateral scleroses (ALS) and familial amyloidotic polyneuropathy (FAP). FAP is encountered often in our clinical work at Shinshu University School of Medicine because our hospital is located in one of the areas reporting the highest incidence of FAP in the world, second only to Portugal. Therefore, myself and my colleagues have taken a special interest in investigating the states of proteases and their inhibitors in neurologic diseases. This chapter briefly summarizes our current state of knowledge concerning the implications of protease and protease inhibitors in ALS and FAP. These developments should provide insights for subsequent steps toward clarifying the etiologies of these diseases.
KeywordsAmyotrophic Lateral Sclerosis Familial Mediterranean Fever Amyloid Fibril Interstitial Cystitis Experimental Allergic Encephalomyelitis
Unable to display preview. Download preview PDF.
- 3.B.W. Festoff, Circulating protease inhibitors in amyotrophic lateral sclerosis: reduced a2 macroglobulin. Ann. NeuroL, 8: 121 (1980).Google Scholar
- 16.G. Holmgren, E. Haettner, I. Nordenso, O.L. Sandgren, L. Steen, and E. Lundgren, (1988) Homozygosity for the transthyretin-met30-gene in two Swedish sibs with familial amyloidotic polyneuropathy. Clin Genet (Denmark) 34 (5) p333–8.Google Scholar
- 26.N. Adachi, C.S. Koh, N. Tsukada, S. Shoji, and N. Yanagisawa, In vitro degradation of amyloid material by four proteases in tissue of a patient with familial amyloidotic polyneuropathy. J.NeuroL Sci, 84:295–299 (1988).Google Scholar
- 27.T. Isobe, and E.F. Osserman, Effects of dimethyl sulphoxide (DMSO) on Bence-Jones proteins, amyloid fibrils and casein-induced amyloidosis. In: Wegelius O, Pastemack A, eds. Amyloidosis. London, New York and San Francisco: Academic Press, 1976:247–57 (1976).Google Scholar
- 28.H. Falck, and O. Wegelius, Treatment of secondary renal amyloidosis with dimethyl sulphoxide. In: Proceedings of European Amyooidosis Research Symposium. Bristol, Sept 10–12, 1981.Google Scholar
- 30.B. Skogen,and E. Amundsen, Degradation of amyloid proteins with protease I from Aspergillus oryzae. In vivo increase in SAA clearance rate after enzyme infusion. Scand. J. ImmunoL 16, 509–514 (1982).Google Scholar
- 35.V.G. Glozman, and I.S.Anchupane, Use of chymotrypsin in inflammatory diseases of the scrotal organs. Urol Nefrol (Musk). (5): 44–6 (1982).Google Scholar
- 36.S. Avakian, Current concepts in therapy. Chymotrypsin and trypsin. N F.ngl J Med. (1961).Google Scholar
- 38.A. Stochino, G. Tecce, and G.G. Tedeschi, Sull’assorbimento intestinal delle proteine omologhe ed eterologhe. Boll Soc ltal Biol Sper 27: 1672–4 (1951).Google Scholar
- 40.RA. Bruce, and K.C. Quinton, Effect of oral a-chymotrypsin on sputum viscosity. Br Med J, 1: 282284 (1962).Google Scholar
- 43.C.R. Abraham, D. J. Selkoe and H. Potter, Immunochemical identification of the serine protease inhibitor, at-antichymotrypsin, in the brain amyloid deposits of Alzheimer’s disease. Cell, 52: 487501 (1988).Google Scholar
- 46.L.S. Perlin, P. Brakman, H.S. Berg, P.I. Kirchner, R.B. Moguin, T. Astrup, Enhanced blood coagulation and fibrinolysis in a patient with primary fibrinolysis. Thromb Haemostasis 26: 9–14 (1971).Google Scholar